Table 2Summary of adverse events of interest

Bedaquiline/BR
N=79 (%)
Placebo/BR
N=81 (%)
Musculoskeletal and connective tissue39 (49.4)40 (49.4)
Myalgia6 (7.6)7 (8.6)
Musculoskeletal pain4 (5.1)4 (4.9)
Rhabdomyolysis/Myopathy00
Gastrointestinal disorders53 (67.1)53 (65.4)
Pancreatitis1 (1.3)0
Increased amylase2 (2.5)1 (1.2)
Nausea32 (40.5)30 (37.0)
Vomiting23 (29.1)22 (27.2)
Upper abdominal pain10 (12.7)7 (8.6)
Gastritis7 (8.9)16 (19.8)

From: 4, Evidence base for policy formulation

Cover of The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis
The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance.
Copyright © World Health Organization 2013.

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.